- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- MB07803, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Walnut Creek, California • Miami, Florida + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LGD-6972, Placebo (Captisol®)
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day, MB07133 1800 mg/m2/day, MB07133 2400 mg/m2/day
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lymphoma
- Interventions
- denileukin diftitox, dexamethasone
- Biological · Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 11
- States / cities
- Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LGD-6972, Placebo (Captisol ®)
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Miami, Florida • Cincinnati, Ohio
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg, Placebo
- Drug · Other
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 29
- States / cities
- Tuscumbia, Alabama • Chandler, Arizona • Surprise, Arizona + 24 more
- Conditions
- Chronic Hepatitis B
- Interventions
- NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
- Drug
- Lead sponsor
- Nucorion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Monterey Park, California
- Conditions
- Lymphoma, T-Cell, Cutaneous
- Interventions
- ONTAK (denileukin difitox, DAB389IL-2)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 9
- States / cities
- Duarte, California • New Haven, Connecticut • Iowa City, Iowa + 6 more
- Conditions
- Hypertension
- Interventions
- PS433540, placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- bexarotene, photopheresis
- Drug · Device
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- erlotinib and bexarotene
- Drug
- Lead sponsor
- Konstantin Dragnev
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • New York, New York
- Conditions
- Hepatitis B
- Interventions
- NCO-48 Fumarate, Placebo
- Drug
- Lead sponsor
- Nucorion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Osteoporosis
- Interventions
- lasofoxifene, placebo
- Drug · Other
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 80 Years · Female only
- Enrollment
- 8,556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • Palm Desert, California + 29 more
- Conditions
- Osteoporosis
- Interventions
- lasofoxifene, raloxifene, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 48 Years to 75 Years · Female only
- Enrollment
- 540 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 72
- States / cities
- Albany, California • Berkeley, California • La Jolla, California + 49 more
- Conditions
- Early Stage Parkinson's Disease
- Interventions
- Aplindore, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hypercholesterolemia
- Interventions
- MB07811, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 11
- States / cities
- San Diego, California • Jacksonville, Florida • Pembroke Pines, Florida + 8 more
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- erlotinib (Tarceva) and bexarotene (Targretin)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Breast Cancer
- Interventions
- bexarotene
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Epilepsy
- Interventions
- Intravenous Carbamazepine (IV CBZ)
- Drug
- Lead sponsor
- Lundbeck LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Torrance, California + 24 more
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Bexarotene
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Palm Springs, California • New Orleans, Louisiana • Hershey, Pennsylvania
- Conditions
- Parapsoriasis
- Interventions
- Bexarotene 1% gel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
- Interventions
- Bexarotene (Targretin®), Erlotinib (Tarceva™)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- Bexarotene (targretin)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- LGD-6972 Solution, LGD-6972 Capsules
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio